Kevin Hern: “So really, we are left just with one option. That is just raise income taxes on everybody to the point where we run out…”

One way to do this is by reducing the regulatory burden so that Title IV-B funding recipients can spend more time helping children and families, and less time waiting through the red tape.

When you’re spending at twice the rate of what your revenue growth is, that’s a problem.

It is sad that what we are dealing with is stifled innovation and a decrease in patient access due to the Inflation Reduction Act.

I will always advocate for those who are suffering from a rare disease and support efforts to bring treatments for these diseases to market.